WWTR1 and sarcoma: Within these TAZ/YAP activated sarcomas, 47% (54/114) demonstrated loss of MST1 expression, 26% (30/117) demonstrated loss of MST2 expression, 19% (22/113) of the sarcomas demonstrated loss of LATS1 expression, and 27% (32/117) of the sarcomas demonstrated loss of LATS2 expression (Figure 1C).